Risk Partners Life Sciences Roundtable 2024, thank you very much! Already for the 26.06.2025 >

Contact us

We congratulate Steyr Motors AG on the successful listing
in the Scale Segment of the German Stock Exchange on October 30, 2024!

Risk Partners had the honor to act as IPO underwriting counsel in this transaction. Our team, led by Florian Eckstein and Björn Stressenreuter, supported Steyr Motors AG in its IPO on the Frankfurt Stock Exchange. Our expertise and comprehensive support were geared towards providing Steyr Motors with a secure and successful start on the capital markets.

We would like to thank Julian Cassutti and Christoph Cerar from Steyr Motors and the team at Mutares SE & Co. KGaA for the successful cooperation and their trust in our expertise.

With this step, Steyr Motors AG has not only gained access to additional capital for further growth, but has also strengthened its position as an innovation leader in the field of engine technology. 

About the Scale Segment of Deutsche Börse

Deutsche Börse's Scale segment offers small and medium-sized companies more straightforward access to the capital market and facilitates the financing of innovation and growth projects. Companies in the Scale segment benefit from a standardized listing process and special advisory networks that help them to master the challenges of the capital market with confidence.

At Risk Partners, we pride ourselves on supporting companies like Steyr Motors AG with specialized insurance solutions and comprehensive advice. From management liability insurance to innovative insurance products specifically tailored to the challenges and opportunities of an IPO, we offer customized solutions for our clients. When going public on a German stock exchange or through our innovative public flip concept when going public on a foreign stock exchange.

Ready for the next step?

For companies that are also looking to go public, Risk Partners offers tailor-made insurance solutions and advice to make this step a safe one. Contact us to find out how we can support you on your journey to the stock market.

Also read our other blog posts

Being Public

Risk Partners supports successful uplisting of Formycon AG to the Prime Standard

Congratulations to Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024! Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the Scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the field of biosimilars! Formycon AG has focused on

Read more "
November 14, 2024
Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
June 7, 2024
Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
October 31, 2023
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
September 26, 2023
Life Sciences

Finance Day 2023

Growth capital for biotechnology: Yesterday, today, tomorrow! A few days ago, Jutta Zaglauer and Florian Eckstein from our team attended the Finance Day 2023 on the occasion of the 25th anniversary of biotechnology at the IZB - Innovation and Startup Center for Biotechnology. The event offered an exciting exchange and insights into current financing and capital market issues of biotechnology companies. As an experienced specialist insurance broker for the areas of life sciences, venture capital and IPOs, all three cornerstones of our "magic expertise triangle" were part of the exciting agenda. It was also interesting to discuss the importance of customized

Read more "
November 6, 2023
Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
April 19, 2024